Menu
X

Can the Million-dollar Anti-cancer Injection “Cure” Tumors?

Can the Million-dollar Anti-cancer Injection “Cure” Tumors?

Is CAR-T therapy really a “one-shot cure”?

And how can we ensure that this CAR “drives well and drives long”?

百万抗癌针能“治愈”肿瘤吗?

如何让CAR“开得好,开得久?”

Expert:

**Jing Pan**

**Associate Chief Physician**

**Department of Pediatric Hematology, Beijing Gaobo Hospital**

**Professional Memberships:**

– Member, Pediatric Oncology Professional Committee of the Chinese Anti-Cancer Association

– Youth Committee Member, Hematologic Oncology Professional Committee of the Chinese Anti-Cancer Association

– Youth Committee Member, Clinical Application Professional Committee of the Chinese Medical Biotechnology Association

**Expertise:**

Dr. Pan currently manages an 80-bed pediatric hematology unit and has extensive experience in pediatric hematology, particularly in CAR-T cell immunotherapy, with nearly 10 years of experience in the field. She is dedicated to stratified CAR-T treatment, optimizing the management of complications during CAR-T therapy, and establishing an efficacy monitoring system post-treatment. Dr. Pan and her team have accumulated one of the largest single-center case collections globally, particularly in the areas of sequential CAR-T therapy for improving long-term outcomes in B-ALL and in exploring autologous and allogeneic CD5, CD7 CAR-T therapy for T-ALL/LBL.

Her related clinical research on CD7 CAR-T, CD19 CAR-T, CD22 CAR-T, and CD19-22 sequential CAR-T has been published in leading international journals such as *Lancet Oncology*, *JCO*, *Blood*, *JHO*, and *Leukemia*. Additionally, she has frequently presented the latest advancements in her team’s immunotherapy research at both domestic and international conferences, including ASCO, ASH, EHA, and JSH.

潘 静

副主任医师

北京高博医院 小儿血液科

中国抗癌协会小儿肿瘤专业委员会专业委员

中国抗癌协会血液肿瘤专业委员会青年委员

中国医药生物技术协会医药生物技术临床应用专业委员会青年委员

擅长:

目前独立管理床位数80张的儿童血液病区。从事儿童血液科临床工作多年,特别是在儿童CAR-T细胞免疫治疗方面积累了近10年的经验。致力于CAR-T的分层治疗,优化CAR-T治疗过程中的并发症处理,建立CAR-T治疗后的疗效监控体系。尤其是其带领团队在序贯CAR-T提高B-ALL远期预后,T-ALL/LBL的自体、异体CD5、CD7CAR-T治疗探索方面目前积累了全球较大的单中心病例数。相关的CD7CAR-T临床研究、CD19CAR-T临床研究、CD22CAR-T临床研究、CD19-22序贯CAR-T研究等,发表在国际血液病权威杂志期刊Lancet on-cology、JC0、Blood、JHO和Leukemia。并多次在国内外学术会议(美国临床肿瘤大会ASCO、美国血液年会ASH、欧洲血液年会EHA、日本血液年会JSH)汇报团队免疫治疗的最新进展。

🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.